Protein glycosylation alterations in hepatocellular carcinoma: function and clinical implications

[1]  Jie-Li Hu,et al.  O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N6-methyladenosine-dependent manner , 2023, Signal Transduction and Targeted Therapy.

[2]  A. Huang,et al.  O-GlcNAcylation of SPOP promotes carcinogenesis in hepatocellular carcinoma , 2023, Oncogene.

[3]  Yan Zhang,et al.  ST6GAL1 inhibits metastasis of hepatocellular carcinoma via modulating sialylation of MCAM on cell surface , 2022, Oncogene.

[4]  Q. Gao,et al.  Immune checkpoint therapy-elicited sialylation of IgG antibodies impairs antitumorigenic type I interferon responses in hepatocellular carcinoma. , 2022, Immunity.

[5]  E. Miyoshi,et al.  Transcription factor SP1 regulates haptoglobin fucosylation via induction of GDP-fucose transporter 1 in the hepatoma cell line HepG2 , 2022, Biochemistry and biophysics reports.

[6]  Y. Ye,et al.  Downregulation of ST6GAL1 Promotes Liver Inflammation and Predicts Adverse Prognosis in Hepatocellular Carcinoma , 2022, Journal of inflammation research.

[7]  Li-ping Wang,et al.  α2,6-Sialylation promotes hepatocellular carcinoma cells migration and invasion via enhancement of nSmase2-mediated exosomal miRNA sorting , 2022, Journal of Physiology and Biochemistry.

[8]  Qin Yang,et al.  Integrated transcriptomics unravels implications of glycosylation-regulating signature in diagnosis, prognosis and therapeutic benefits of hepatocellular carcinoma , 2022, Comput. Biol. Medicine.

[9]  Fugen Shangguan,et al.  N-glycosylation stabilizes MerTK and promotes hepatocellular carcinoma tumor growth , 2022, Redox biology.

[10]  Yanru Guo,et al.  HOTAIR modulates hepatocellular carcinoma progression by activating FUT8/core-fucosylated Hsp90/MUC1/STAT3 feedback loop via JAK1/STAT3 cascade. , 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[11]  Han Yang,et al.  SLC35B4 Stabilizes c-MYC Protein by O-GlcNAcylation in HCC , 2022, Frontiers in Pharmacology.

[12]  Wei Wei,et al.  Long noncoding RNA TINCR facilitates hepatocellular carcinoma progression and dampens chemosensitivity to oxaliplatin by regulating the miR-195-3p/ST6GAL1/NF-κB pathway , 2022, Journal of experimental & clinical cancer research : CR.

[13]  Jianing Zhang,et al.  Knockdown of ST6Gal‐I expression in human hepatocellular carcinoma cells inhibits their exosome‐mediated proliferation‐ and migration‐promoting effects , 2021, IUBMB life.

[14]  Yiqun Li,et al.  NEU4 inhibits motility of HCC cells by cleaving sialic acids on CD44 , 2021, Oncogene.

[15]  J. Yun,et al.  Glucose deprivation induced aberrant FUT1-mediated fucosylation drives cancer stemness in hepatocellular carcinoma. , 2021, The Journal of clinical investigation.

[16]  Hao Wang,et al.  N‐glycan fingerprint predicts alpha‐fetoprotein negative hepatocellular carcinoma: A large‐scale multicenter study , 2021, International journal of cancer.

[17]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[18]  H. Eguchi,et al.  ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma , 2020, Clinical Cancer Research.

[19]  T. Masaki,et al.  A Potential Serum N-glycan Biomarker for Hepatitis C Virus-Related Early-Stage Hepatocellular Carcinoma with Liver Cirrhosis , 2020, International journal of molecular sciences.

[20]  E. Zenteno,et al.  Relevance of glycans in the interaction between T lymphocyte and the antigen presenting cell , 2020, International reviews of immunology.

[21]  H. Liu,et al.  O-GlcNAcylation of SIX1 enhances its stability and promotes Hepatocellular Carcinoma Proliferation , 2020, Theranostics.

[22]  C. Zhang,et al.  Caveolin‐1 upregulates Fut8 expression by activating the Wnt/β‐catenin pathway to enhance HCC cell proliferative and invasive ability , 2020, Cell biology international.

[23]  Qingshan Li,et al.  Heterogeneities of Site-Specific N-Glycosylation in HCC Tumors With Low and High AFP Concentrations , 2020, Frontiers in Oncology.

[24]  Y. Iwashita,et al.  Altered glycosylation associated with dedifferentiation of hepatocellular carcinoma: a lectin microarray-based study , 2020, BMC Cancer.

[25]  Manal M. Hassan,et al.  IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. , 2019, The Journal of clinical investigation.

[26]  C. Reis,et al.  Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading? , 2019, Cancer cell.

[27]  Jun Zhou,et al.  Reciprocal Regulation Between O-GlcNAcylation and β-Catenin Facilitates Cell Viability and Inhibits Apoptosis in Liver Cancer. , 2019, DNA and cell biology.

[28]  Xiao-lian Zhang,et al.  Hepatitis C Virus-Induced FUT8 Causes 5-FU Drug Resistance in Human Hepatoma Huh7.5.1 Cells , 2019, Viruses.

[29]  J. Novak,et al.  Glycosylation in health and disease , 2019, Nature Reviews Nephrology.

[30]  Q. Gao,et al.  O‐GlcNAc transferase activates stem‐like cell potential in hepatocarcinoma through O‐GlcNAcylation of eukaryotic initiation factor 4E , 2019, Journal of cellular and molecular medicine.

[31]  Yun-sheng Zhao,et al.  Clinical significance of fucosylated GP73 in the differential diagnosis of hepatocellular carcinoma , 2018, The International journal of biological markers.

[32]  Weicheng Wu,et al.  O-GlcNAcylation on Rab3A attenuates its effects on mitochondrial oxidative phosphorylation and metastasis in hepatocellular carcinoma , 2018, Cell Death & Disease.

[33]  R. Drake,et al.  N-Linked Glycan Branching and Fucosylation Are Increased Directly in Hcc Tissue As Determined through in Situ Glycan Imaging. , 2018, Journal of proteome research.

[34]  H. Hsu,et al.  Unmasking Fucosylation: from Cell Adhesion to Immune System Regulation and Diseases. , 2018, Cell chemical biology.

[35]  Zhi-Nan Chen,et al.  N‐glycosylation by N‐acetylglucosaminyltransferase V enhances the interaction of CD147/basigin with integrin β1 and promotes HCC metastasis , 2018, The Journal of pathology.

[36]  Chi‐Huey Wong,et al.  An Alkynyl-Fucose Halts Hepatoma Cell Migration and Invasion by Inhibiting GDP-Fucose-Synthesizing Enzyme FX, TSTA3. , 2017, Cell chemical biology.

[37]  Anh Tuan Nguyen,et al.  Organelle Specific O-Glycosylation Drives MMP14 Activation, Tumor Growth, and Metastasis. , 2017, Cancer cell.

[38]  J. Gu,et al.  Inhibition of fucosylation by 2-fluorofucose suppresses human liver cancer HepG2 cell proliferation and migration as well as tumor formation , 2017, Scientific Reports.

[39]  H. Kuo,et al.  High expression FUT1 and B3GALT5 is an independent predictor of postoperative recurrence and survival in hepatocellular carcinoma , 2017, Scientific Reports.

[40]  K. Guo,et al.  Sorafenib induced alteration of protein glycosylation in hepatocellular carcinoma cells , 2017, Oncology letters.

[41]  Q. Pan,et al.  The essential role of YAP O-GlcNAcylation in high-glucose-stimulated liver tumorigenesis , 2017, Nature Communications.

[42]  Xi Chen,et al.  Alteration of N-glycan expression profile and glycan pattern of glycoproteins in human hepatoma cells after HCV infection. , 2017, Biochimica et biophysica acta. General subjects.

[43]  P. Patel,et al.  Glycosylation: a hallmark of cancer? , 2016, Glycoconjugate Journal.

[44]  X. Qin,et al.  Aided Diagnosis of Hepatocellular Carcinoma Using Serum Fucosylated Haptoglobin Ratios , 2017, Journal of Cancer.

[45]  Y. Miao,et al.  MiRNA expression profiles reveal the involvement of miR-26a, miR-548l and miR-34a in hepatocellular carcinoma progression through regulation of ST3GAL5 , 2017, Laboratory Investigation.

[46]  Mingming Sun,et al.  Sialyltransferase ST3GAL6 mediates the effect of microRNA‐26a on cell growth, migration, and invasion in hepatocellular carcinoma through the protein kinase B/mammalian target of rapamycin pathway , 2017, Cancer science.

[47]  Jianxin Gu,et al.  Loss of N-Acetylgalactosaminyltransferase-4 Orchestrates Oncogenic MicroRNA-9 in Hepatocellular Carcinoma* , 2017, The Journal of Biological Chemistry.

[48]  Stefan Burén,et al.  Regulation of OGT by URI in Response to Glucose Confers c-MYC-Dependent Survival Mechanisms. , 2016, Cancer cell.

[49]  Jianing Zhang,et al.  ST6Gal-I modulates docetaxel sensitivity in human hepatocarcinoma cells via the p38 MAPK/caspase pathway , 2016, Oncotarget.

[50]  Xi Chen,et al.  Oncotargets and Therapy Dovepress Dovepress Overexpression of St3gal-i Promotes Migration and Invasion of Hcclm3 in Vitro and Poor Prognosis in Human Hepatocellular Carcinoma Qing-jie Song , 2022 .

[51]  K. Guo,et al.  GP73 N-glycosylation at Asn144 reduces hepatocellular carcinoma cell motility and invasiveness , 2016, Oncotarget.

[52]  Y. Li,et al.  Specific N-glycans of Hepatocellular Carcinoma Cell Surface and the Abnormal Increase of Core-α-1, 6-fucosylated Triantennary Glycan via N-acetylglucosaminyltransferases-IVa Regulation , 2015, Scientific Reports.

[53]  S. Pinho,et al.  Glycosylation in cancer: mechanisms and clinical implications , 2015, Nature Reviews Cancer.

[54]  K. Ohtsubo,et al.  Loss of αl,6‐fucosyltransferase inhibits chemical‐induced hepatocellular carcinoma and tumorigenesis by down‐regulating several cell signaling pathways , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[55]  K. Guo,et al.  Serum fucosylated paraoxonase 1 as a potential glycobiomarker for clinical diagnosis of early hepatocellular carcinoma using ELISA Index , 2015, Glycoconjugate Journal.

[56]  H. Juan,et al.  Knockdown of GALNT1 suppresses malignant phenotype of hepatocellular carcinoma by suppressing EGFR signaling , 2015, Oncotarget.

[57]  Christopher J. Gregg,et al.  A red meat-derived glycan promotes inflammation and cancer progression , 2014, Proceedings of the National Academy of Sciences.

[58]  D. Pan,et al.  Decreased Expression of Hepatocyte Nuclear Factor 4α (Hnf4α)/MicroRNA-122 (miR-122) Axis in Hepatitis B Virus-associated Hepatocellular Carcinoma Enhances Potential Oncogenic GALNT10 Protein Activity* , 2014, The Journal of Biological Chemistry.

[59]  I. Lai,et al.  C1GALT1 Promotes Invasive Phenotypes of Hepatocellular Carcinoma Cells by Modulating Integrin β1 Glycosylation and Activity , 2014, PloS one.

[60]  Ziding Feng,et al.  Mass-Selected Site-Specific Core-Fucosylation of Ceruloplasmin in Alcohol-Related Hepatocellular Carcinoma , 2014, Journal of proteome research.

[61]  Ziding Feng,et al.  Analysis of Serum Haptoglobin Fucosylation in Hepatocellular Carcinoma and Liver Cirrhosis of Different Etiologies , 2014, Journal of proteome research.

[62]  Chung-Yi Wu,et al.  Downregulation of microRNA‐15b by hepatitis B virus X enhances hepatocellular carcinoma proliferation via fucosyltransferase 2‐induced Globo H expression , 2014, International journal of cancer.

[63]  H. Zhou,et al.  FUT family mediates the multidrug resistance of human hepatocellular carcinoma via the PI3K/Akt signaling pathway , 2013, Cell Death and Disease.

[64]  Rey-Heng Hu,et al.  C1GALT1 enhances proliferation of hepatocellular carcinoma cells via modulating MET glycosylation and dimerization. , 2013, Cancer research.

[65]  S. Nishimura,et al.  Identification of novel serum biomarkers of hepatocellular carcinoma using glycomic analysis , 2013, Hepatology.

[66]  Shengjin Yu,et al.  Caveolin‐1 up‐regulates integrin α2,6‐sialylation to promote integrin α5β1‐dependent hepatocarcinoma cell adhesion , 2013, FEBS letters.

[67]  Yin-kun Liu,et al.  Serum paraoxonase 1 heteroplasmon, a fucosylated, and sialylated glycoprotein in distinguishing early hepatocellular carcinoma from liver cirrhosis patients. , 2012, Acta biochimica et biophysica Sinica.

[68]  Stuart M Haslam,et al.  Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome. , 2012, Nature chemical biology.

[69]  Lawrence A Tabak,et al.  Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. , 2012, Glycobiology.

[70]  Qianqian Zhu,et al.  O-GlcNAcylation plays a role in tumor recurrence of hepatocellular carcinoma following liver transplantation , 2012, Medical Oncology.

[71]  Mary Ann Comunale,et al.  Increased Levels of Tetra-antennary N-Linked Glycan but Not Core Fucosylation Are Associated with Hepatocellular Carcinoma Tissue , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[72]  Po-Huang Lee,et al.  Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor. , 2011, Cancer research.

[73]  M. Aebi,et al.  Mechanisms and principles of N-linked protein glycosylation. , 2011, Current opinion in structural biology.

[74]  Mary Ann Comunale,et al.  Linkage Specific Fucosylation of Alpha-1-Antitrypsin in Liver Cirrhosis and Cancer Patients: Implications for a Biomarker of Hepatocellular Carcinoma , 2010, PloS one.

[75]  Shuhan Sun,et al.  N‐glycan based models improve diagnostic efficacies in hepatitis B virus‐related hepatocellular carcinoma , 2010, International journal of cancer.

[76]  Joris R Delanghe,et al.  Diagnostic value of the hemopexin N-glycan profile in hepatocellular carcinoma patients. , 2010, Clinical chemistry.

[77]  Chen Li,et al.  Identification and confirmation of biomarkers using an integrated platform for quantitative analysis of glycoproteins and their glycosylations. , 2010, Journal of proteome research.

[78]  G. Hart,et al.  The intersections between O-GlcNAcylation and phosphorylation: implications for multiple signaling pathways , 2010, Journal of Cell Science.

[79]  Mary Ann Comunale,et al.  Novel Fucosylated Biomarkers for the Early Detection of Hepatocellular Carcinoma , 2009, Cancer Epidemiology Biomarkers & Prevention.

[80]  C. Van Steenkiste,et al.  Alteration of protein glycosylation in liver diseases. , 2009, Journal of hepatology.

[81]  Y. Mechref,et al.  Detection of Hepatocellular Carcinoma Using Glycomic Analysis , 2009, Clinical Cancer Research.

[82]  Mary Ann Comunale,et al.  Identification and development of fucosylated glycoproteins as biomarkers of primary hepatocellular carcinoma. , 2009, Journal of proteome research.

[83]  N. Hayashi,et al.  A high expression of GDP-fucose transporter in hepatocellular carcinoma is a key factor for increases in fucosylation. , 2007, Glycobiology.

[84]  T. Nakagawa,et al.  Biological function of fucosylation in cancer biology. , 2007, Journal of biochemistry.

[85]  R. Contreras,et al.  N‐glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus , 2007, Hepatology.

[86]  Masato Takahashi,et al.  N-glycan alterations are associated with drug resistance in human hepatocellular carcinoma , 2007, Molecular Cancer.

[87]  O. J. Semmes,et al.  Lectin Capture Strategies Combined with Mass Spectrometry for the Discovery of Serum Glycoprotein Biomarkers* , 2006, Molecular & Cellular Proteomics.

[88]  Mary Ann Comunale,et al.  Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. , 2006, Journal of proteome research.

[89]  N. Hayashi,et al.  Relationship between elevated FX expression and increased production of GDP-L-fucose, a common donor substrate for fucosylation in human hepatocellular carcinoma and hepatoma cell lines. , 2003, Cancer research.

[90]  S. Satomura,et al.  AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[91]  B. Samyn-Petit,et al.  The human sialyltransferase family. , 2001, Biochimie.

[92]  Naoyuki Taniguchi,et al.  Gene expression of α1‐6 fucosyltransferase in human hepatoma tissues: A possible implication for increased fucosylation of α‐fetoprotein , 1998 .

[93]  S. Nagataki,et al.  Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. , 1993, The New England journal of medicine.

[94]  K. Taketa,et al.  Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. , 1990, Gastroenterology.

[95]  Huaiqian Dou,et al.  Fucosylation in cancer biology and its clinical applications. , 2019, Progress in molecular biology and translational science.

[96]  Timothy Block,et al.  Glycosylation and liver cancer. , 2015, Advances in cancer research.

[97]  Gerald W. Hart,et al.  The O-GlcNAc Modification , 2009 .

[98]  K. Suzuki,et al.  Gene expression of alpha1-6 fucosyltransferase in human hepatoma tissues: a possible implication for increased fucosylation of alpha-fetoprotein. , 1998, Hepatology.

[99]  M. Monsigny,et al.  Increased alpha2,6 sialylation of N-glycans in a transgenic mouse model of hepatocellular carcinoma. , 1997, Cancer research.